Early clinical trial results, presented at addiction medicine conferences in 2024 and 2025, have reported that participants on semaglutide experienced fewer heavy drinking days, lower craving scores on validated assessment tools, and in some cohorts spontaneous reductions in other substance use that wasnt being directly targeted
Is compounded semaglutide safe for treating off-label neurological effects
Within the same period, the dispensed prescriptions within the benefit to incident patients with a preexisting diagnosis of obesity without T2DM increased by 270% (4.0 to 14.6%), and 502% for patients with neither obesity nor T2DM (5.3 to 32.1%), and 515% for patients without any of the included diagnoses (4.2 to 25.7%) (see Table 9 in the Appendix)
Since the FDA approved Wegovy in 2021 and Zepbound in 2023, public awareness of GLP-1 drugs have surged
In addition, an obesity first strategy should be implemented for animals suffering from chronic conditions such as osteoarthritis, insulin resistance, cardiovascular and respiratory conditions, hypertension, and more
